Press "Enter" to skip to content

Loxo, Bayer drug for cancers driven by rare mutation gets U.S. nod

A Loxo Oncology Inc drug shown to be effective against a wide variety of cancers driven by a single, rare genetic mutation has won U.S. approval, the Food and Drug Administration announced on Monday.

Original source:

Also Read:   Mnuchin says U.S. coronavirus aid bill cost should be significant, not huge